Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus

Endocrine Practice

Volumn 18, Issue 1, 2012, Pages 17-25

  Levin, Philip A ^a   Mersey, James H ^a   Zhou, Steven ^b   Bromberger, Lee A ^a  

^a GREATER BALTIMORE MEDICAL CENTER   (United States)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; EXENDIN 4; HEMOGLOBIN A1C; INSULIN GLARGINE; METFORMIN;

ADULT; ARTICLE; BODY WEIGHT; DISEASE DURATION; DRUG WITHDRAWAL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84857531976     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP11097.OR     Document Type: Article

References (17)

1. Östgren CJ, Lindblad U, Ranstam J, Melander A, Råstam L; Skaraborg hypertension and Diabetees Project. Glycaemic control, disease duration and beta-cell function in patients with type 2 diabetes in a Swedish community. Skaraborg Hypertension and Diabetes Project. Diabet Med. 2002;19:125-129.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [Erratum in Lancet. 1999;354:602]. Lancet. 1998;352: 837-853.
3. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initia-tion and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
4. Home PD, Fritsche A, Schinzel S, Massi-Benedetti M. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. Diabetes Obes Metab. 2010;12: 772-779.
5. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: ran-domized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003; 26:3080-3086.
6. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insu-lin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005;28:950-955.
7. Forst T, Larbig M, Hohberg C, et al. Adding insulin glargine vs. NPH insulin to metformin results in a more effi-cient postprandial beta-cell protection in individuals with type 2 diabetes. Diabetes Obes Metab. 2010;12:437-441.
8. Rodbard HW, Blonde L, Braithwaite SS, et al. American Association of Clinical Endocrinologists medical guide-lines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(Suppl 1):1-68.
9. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005; 143:559-569.
10. Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007;29:2333-2348.
11. Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care. 2010;33:1509-1515.
12. Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract. 2007;13:444-450.
13. Sheffield CA, Kane MP, Busch RS, Bakst G, Abelseth JM, Hamilton RA. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract. 2008;14:285-292.
14. Yoon NM, Cavaghan MK, Brunelle RL, Roach P. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocri-nology outpatient setting. Clin Ther. 2009;31:1511-1523.
15. Nayak UA, Govindan J, Baskar V, Kalupahana D, Singh BM. Exenatide therapy in insulin-treated type 2 dia-betes and obesity. QJM. 2010;103:687-694.
16. Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc; 2007.
17. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154:103-112.